

Receipt date: 08/04/2005

10524800 GAO 1531  
JC06 Rec'd PCT/PTO 04 AUG 2005

Approved for use through 08/30/2003. PTO/SB/21 (08-03)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/524,302	
	Filing Date	July 28, 2003	
	First Named Inventor	Stephan Schwerts	
	Art Unit	Unassigned	
	Examiner Name	Unassigned	
Mail Stop	Amendment	Attorney Docket Number	1300-0014

**ENCLOSURES (Check all that apply)**

<input checked="" type="checkbox"/> <b>No fee due</b> <input type="checkbox"/> Fee Transmittal <input type="checkbox"/> Fee(s) due <input type="checkbox"/> Fee Transmittal <input type="checkbox"/> Check for \$ <input checked="" type="checkbox"/> <b>Charge any underpayment or credit any overpayment to Deposit Account No. 18-0580</b> <input checked="" type="checkbox"/> <b>Return postcard</b> <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input checked="" type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> <b>Information Disclosure Statement &amp; Form(s) PTO-1449</b> <input checked="" type="checkbox"/> <b>Copies of cited references (AA-AF)</b> <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts / Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Request to Add Omitted Inventor in Provisional Application Under 37 CFR 1.48(d) <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s):	<input type="checkbox"/> After Allowance Communication to a Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks:		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual Name (print/type)	David A. Sadewasser, Reg. No. 55,587 Reed Intellectual Property Law Group	Telephone	(650) 251-7700
Signature	<i>David A. Sadewasser</i>	Date	August 2, 2005

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Name (print/type)	Joe Clark		
Signature	<i>Joe Clark</i>	Date	August 2, 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of:  
Stephen SCHWERS et al.

Serial No.: 10/524,302

Group Art Unit: Unassigned

Intl. Filing Date: July 28, 2003

Examiner: Unassigned

Title: GENETIC POLYMORPHISMS SENSITIVELY PREDICTING ADVERSE DRUG  
REACTIONS (ADR) AND DRUG EFFICACY

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(b)(3)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the Examiner review and make of record the references identified in this paper. A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

U.S. PATENT DOCUMENTS		
Document No.	Issue Date / Publication Date	Patentee / Applicant

FOREIGN PATENT DOCUMENTS		
Document No.	Publication Date	Country
WO 99/64630	12/16/99	PCT


OTHER DOCUMENTS
ASSMANN, et al., <i>Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men</i> , Am. J. Cardiol. 77:1179-1184 (1996).
LAZAROU, <i>Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies</i> , J. Am. Med. Assoc. 279:1200-1205 (1998).
LUSIS, <i>Atherosclerosis</i> , Nature 407:233-241 (2000).
ROSS, <i>The pathogenesis of atherosclerosis: a perspective for the 1990s</i> , Nature 362:801-809 (1993).
UCAR, et al., <i>HMG-CoA reductase inhibitors and myotoxicity</i> , Drug Safety 22:441-457 (2000).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Office Action on the merits, pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required for filing this Information Disclosure Statement; however, if the Office deems that a fee is necessary to process this paper, the Commissioner is authorized to charge such fee to Deposit Account No. 18-0580.

Respectfully submitted,

By:

  
David A. Sadewasser  
Registration No. 55,587

REED IP LAW GROUP  
1400 Page Mill Road  
Palo Alto, California 94304  
(650) 251-7700 Telephone  
(650) 251-7739 Facsimile

F:\Document\9950\0002\10\Supp IDS

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Application Number</b>	10/524,302
		<b>Int'l. Filing Date</b>	July 28, 2003
		<b>First Named Inventor</b>	Stephen SCHWERS, et al.
		<b>Art Unit</b>	Not Yet Assigned
		<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	1	<b>of</b>	1
		<b>Attorney Docket Number</b>	1300-0014

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
/MKZ/	AA	WO 99/64630	12/16/99	PCT			

OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
/MKZ/	AB	ASSMANN, et al., <i>Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men</i> , Am. J. Cardiol. 77:1179-1184 (1996).					
/MKZ/	AC	LAZAROU, <i>Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies</i> , J. Am. Med. Assoc. 279:1200-1205 (1998).					
/MKZ/	AD	LUSIS, <i>Atherosclerosis</i> , Nature 407:233-241 (2000).					
/MKZ/	AE	ROSS, <i>The pathogenesis of atherosclerosis: a perspective for the 1990s</i> , Nature 362:801-809 (1993).					
/MKZ/	AF	UCAR, et al. <i>HMG-CoA reductase inhibitors and myotoxicity</i> , Drug Safety 22:441-457 (2000).					

<b>Examiner Signature</b>	/Mary K Zeman/	<b>Date Considered</b>	10/22/2008
---------------------------	----------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.